MedNet.nl: People without diabetes who took the new obesity drug amycretin lost 13% of their bodyweight in 12 weeks. Amycretin was shown to be safe and reliable in this first study of people taking the amylin/GLP-1 receptor agonist.
12-09-2024 | Obesity | News